Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-368 |
Synonyms | |
Therapy Description |
ABBV-368 is an activating monoclonal antibody to the T-cell receptor, TNFRSF4 (OX40, CD134) (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-368 | ABBV368|ABBV 368 | OX40 Antibody 14 | ABBV-368 is an activating monoclonal antibody to the T-cell receptor, TNFRSF4 (OX40, CD134) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03071757 | Phase I | ABBV-368 ABBV-368 + Nivolumab | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT03818542 | Phase I | ABBV-927 ABBV-368 Budigalimab | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |